About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Obstructive Sleep Apnea and Diabetes Mellitus | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT00876980

Obstructive Sleep Apnea and Diabetes Mellitus

The investigators hypothesize that obstructive sleep apnea (OSA) contributes to impaired glucose homeostasis and associated vasculopathy, and nCPAP treatment of OSA should improve glycemic control and...

Lead sponsor: The University of Hong Kong•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The University of Hong Kong

Obstructive sleep apnoea (OSA) has been reported to be common (17%) in patients with diabetes mellitus (DM). Both OSA and DM are highly associated with cardiovascular morbidity and mortality. There is growing evidence that OSA may trigger or worsen pre-existing adverse metabolic profile indicative of cardiovascular risk. Treatment of OSA with nasal Continuous Positive Airway Pressure (nCPAP) has been shown to reduce blood pressure and hence to reduce the risk of atherogenesis. In patients with DM, the therapeutic effect of nCPAP is still not known, it would be important to delineate any independent effect of OSA on DM and the therapeutic effect of nCPAP on glycemic control to reduce the long term risk of macrovascular and microvascular complications.

Age

25 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients with type II DM on a stable medication regimen (on diet / oral hypoglycaemic agents / insulin injections)
•2. Age 25 - 70 years
•3. HbA1C \> 7%
•4. AHI \>= 15
•5. Able to give written informed consent

Exclusion Criteria

•1. Patients with severe co-existing illness or poor functional performance
•2. Patients with peripheral vascular diseases, vasculitis / Raynaud's syndrome or thrombocytopenia
•3. Sleep disorders other than OSA
•4. Patients who refuse nCPAP treatment for OSA
•5. Excessive sleepiness causing potential harm (e.g. driver)
•6. HbA1C \>=7%
•7. Habitual drinker (defined as more than 3 times a week)
•8. Pregnant or lactating women

Related studies

Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

NCT05052216 · Pediatric Obstructive Sleep Apnea

RECRUITINGPhase 1

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT07590193 · Diabetes Mellitus, Type 2

RECRUITINGPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

NCT07225686 · Obesity, Obstructive Sleep Apnea

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035 · Diabetes Mellitus, Type 2, Depressive Symptoms, and more

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 16, 2013Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment64

Start dateMay 2008

Last updatedOct 16, 2013

Condition

Obstructive Sleep Apnea Diabetes Mellitus

Locations shown

Queen Mary Hospital, University Department of Medicine

Pokfulam, Hong Kong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 16, 2013Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions